SOD2 expression was not affected by patients’ age, high FIGO tumor stage (stage 1–2 vs 3–4), presence of significant blood markers (yes vs no), histology (clear cell carcinoma vs endometrioid carcinoma), and optimality of adjuvant primary treatment (yes vs no) (Table 1). Here, SOD2 is linked to endometrioid adenocarcinoma.